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Renal cell carcinoma (RCC) ranks in the top-ten list of malignancies both in males and females [1],
and its frequency is increasing as a consequence of the increase in aging and obesity in Western
societies [2]. Clear cell renal cell carcinoma (CCRCC) is by far the most common histological variant [3].
CCRCC has received much attention in recent years due to some new therapeutic approaches that are
improving the life expectancy of many of these patients. In this way, a tumor traditionally resistant
to chemo- and radiotherapy, in which only surgery and early detection had a significant prognostic
impact, is becoming ultimately treatable with evident success with antiangiogenic drugs and immune
checkpoint blockade, either alone or in combination [4]. However, the problem is far from being solved
in many cases, due in part to intra- and inter-tumor heterogeneity [4,5].
Roughly 30% of RCCs are other than CCRCC. The list of non-CCRCC tumors grows steadily, and
includes classically recognized entities and new ones which are sometimes not yet fully characterized [6].
The maze is particularly complex in the field of RCC with papillary architecture. The classical papillary
renal cell carcinoma (PRCC) included types 1 and 2, but today this classification seems insufficient and
is no longer recommended [7]. A recent study has identified a new subtype (type 3) with a distinct
molecular signature and morphologic overlapping with types 1 and 2 [8]. As a result of this complexity,
the diagnosis of PRCC is increasingly becoming a descriptive term among practical pathologists.
To make matters worse, some oncocytic/eosinophilic RCCs (other than ChRCC/oncocytoma) may
display papillary, tubule-papillary or solid-papillary architectures. These cases represent a challenge
even for experienced pathologists, who used to shelter their diagnoses under the descriptive term
“oncocytic papillary renal cell carcinoma”. This descriptive diagnosis, although not very informative, is
still valid for the patient since it includes critical data such as tumor grade, necrosis, staging. However,
the impression is that the term is too broad for use in daily practice.
Probably more than in any other human neoplasm, CCRCC and PRCC are hostages of the
terminology’s restrictions. Strictly speaking, CCRCC was the classical name given to RCC composed
of clear cells and PRCC the one for RCCs architecturally arranged in the papillae, but experience
has shown that some CCRCC are not composed of clear cells and some PRCC do not show papillae.
Moreover, CCRCC may display a predominantly papillary architecture [9] and PRCC a prominent
cytoplasmic clearance [10]. Even worse, some RCC includes different overlapping cell types and
architectures, intermingled altogether in different proportions [11]. Currently, we include these cases in
the “unclassified” category. The broad spectrum of morphological appearances may be quite confusing,
as has been shown in a recent study [12].
Renal oncocytoma (RO) and ChRCC are the best-characterized eosinophilic renal tumors under
the microscope [13]. However, a papillary architecture has been very recently described in ChRCC [14],
thus favoring diagnostic confusion. The use of the term “oncocytic”, applied to cells with large and
deeply granular eosinophilic cytoplasm, is a mistake because, although all oncocytes are eosinophilic,
not all eosinophilic cells are oncocytes. As a consequence, the terms eosinophilic and oncocytic are
exchanged erroneously with some frequency. The elusive word “hybrid” is applied to those cases that
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seem to fall in between RO and ChRCC with very unprecise limits [13]. Some of them likely represent
genomic RO [15]. Such hybrid oncocytic tumors are also observed in the so-called renal oncocytosis, a
condition characterized by multifocal and bilateral oncocytic tumors [16].
Regarding molecular analyses, the issue remains incomplete when considering VHL gene
malfunctions as the hallmark of CCRCC, and the trisomy of chromosomes 7 and 17 as the signature for
PRCC. We know that a subset of CCRCC is VHL wild-type [17] and that PRCC may display a wide
spectrum of molecular alterations [18]. Therefore, the classification of most RCCs based on molecular
signatures is also imperfect and still under construction. Is there any molecular signature specifically
linked to the papillary phenotype regardless of the RCC subtype? We do not know the answer to date,
but we could hypothesize and, in such a case, the papillary architecture will not be a tumor-specific
mark anymore, but a mere trait.
A reductionist prejudice when identifying the varied morphological subtypes of RCC is to link
tumor morphology with a precise site of origin along the nephron. As far as we know, a reliable
analysis linking CCRCC and PRCC to the proximal convoluted tubule is lacking, and there are no
scientific reasons to deny that other elements of the nephron cannot be a potential site of origin for
kidney tumors. How might the proximal convoluted tubule be the origin of two different tumors if
only one cell type has been histologically described there? This question also remains unanswered, but
Gu et al. [19], based on a modeling study on renal cell carcinoma in mice, have proposed that CCRCC
may originate in Bowman’s capsule.
The list of new renal cell neoplasms, either recognized as true entities or pending recognition, is
still growing, as it has been recently reviewed [6]. Many of them may show some morphologic overlap,
so strategic approaches based on immunohistochemistry have been developed trying to overcome this
question [20]. The problem at this point is their correct identification in routine practice, since many of
them are histologically indistinguishable and are defined only by molecular analyses [21] that are not
always performed. This situation leads to the question of how many of these newly described cases are
buried in pathology labs under irrecoverable descriptive diagnoses. As several of these diagnoses carry
out prognostic and eventually therapeutic implications, the reversal of this situation seems an urgent
task for pathologists now that personalized oncology is being increasingly implemented worldwide.
This Special Issue of Cancers regards the RCC labyrinth from very different perspectives, including
the intimate basic mechanisms governing this disease and the clinical practice principles of their
diagnoses and treatments. Thus, the interested reader will have the opportunity to discover some
of the most recent findings in renal carcinogenesis and be updated with excellent reviews on new
therapeutic approaches and the genetic bases of the disease.
Original articles in this issue show interesting findings with potential clinical application. Examples
of the science and research presented in this Special Issue include: the influence of VHL deletion in the
expression of an unfavorable genetic pattern in CCRCC [22]; how a low dose of curcumin inhibits RCC’s
metastatic behavior [23]; the predictive value of the overexpression of EVI1 in CCRCC [24]; the poor
outcome of ChRCC patients who lose CDKN1A mRNA and protein expression [25]; the identification of
distinct signatures of CCRCC progression through in-depth mapping of urinary N-glycoproteome [26];
how a preclinical evaluation method may evaluate the response to targeted therapies in patients with
RCC [27]; the RNA sequencing results obtained in two examples of collecting duct renal cell carcinoma,
an aggressive rare variant of RCC [28]; how GSTO1*CC genotype predicts shorter survival in CCRCC
male patients [29]; the importance of MTA2 as a biomarker of metastatic progression in RCC [30];
the metabolic reprograming in RCC [31]; the prognostic implications of pAMPK immunostaining and
its association with SMAD protein expression in CCRCC [32]; the different amount of chromosomal
losses in classic ChRCC compared with the eosinophilic subtype of this neoplasm [33]; the potential
influence of circular RNAs in CCRCC prognosis [34]; the association of interleukins 4Rα and 13Rα1
with the progression of RCC [35]; the glutathione metabolism in PRCC [36]; how the profiling of
primary and metastatic samples of CCRCC reveals a high homology of metastases with a specific
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subregion of the primary tumor [37]; the interrelationship between serum uric acid levels and RCC
survival [38]; and the importance of ghrelin promoting RCC invasion [39].
A total of nine reviews have also been published. Predominantly clinical reviews deal with the
emerging new therapeutic landscape of metastatic renal cancer [40–43], the genetic approach to this
complex disease [44–47], and the histopathological diagnostic criteria of newly appearing entities [48].
A brief report shows how hypertonicity-affected genes are differentially expressed in CCRCC
correlating with cancer survival [49]. Finally, a short commentary focuses on the therapeutic possibilities
of sarcomatoid RCC [50].
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